Multimodal oculomotor assessment reveals prodromal markers of Parkinson's disease in non-manifesting LRRK2 G2019S mutation carriers.

Autor: Riek HC; Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada. heidi.riek@queensu.ca., Visanji NP; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, University Health Network, Toronto, ON, Canada.; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.; Krembil Brain Institute, University Health Network, Toronto, ON, Canada.; Rossy PSP Centre, University Health Network, Toronto, ON, Canada., Pitigoi IC; Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada., Di Luca DG; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, University Health Network, Toronto, ON, Canada.; Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA., Armengou-Garcia L; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, University Health Network, Toronto, ON, Canada., Ahmed N; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, University Health Network, Toronto, ON, Canada., Perkins JE; Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada., Brien DC; Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada., Huang J; Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada., Coe BC; Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada., Huang J; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, University Health Network, Toronto, ON, Canada., Ghate T; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, University Health Network, Toronto, ON, Canada., Lang AE; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, University Health Network, Toronto, ON, Canada.; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.; Krembil Brain Institute, University Health Network, Toronto, ON, Canada.; Rossy PSP Centre, University Health Network, Toronto, ON, Canada., Marras C; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, University Health Network, Toronto, ON, Canada.; Krembil Brain Institute, University Health Network, Toronto, ON, Canada., Munoz DP; Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada.; Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Jazyk: angličtina
Zdroj: NPJ Parkinson's disease [NPJ Parkinsons Dis] 2024 Dec 19; Vol. 10 (1), pp. 234. Date of Electronic Publication: 2024 Dec 19.
DOI: 10.1038/s41531-024-00840-w
Abstrakt: Oculomotor behaviour changes in patients with Parkinson's disease (PD) are a promising source of prodromal disease markers. Capitalizing on this phenomenon to facilitate early diagnosis requires oculomotor assessment in prodromal cohorts. We examined oculomotor behaviour in non-manifesting LRRK2 G2019S mutation carriers (LRRK2-NM), who have heightened PD risk.Seventeen LRRK2-NM participants, 47 patients with idiopathic PD, and 63 healthy age-matched control participants completed an interleaved pro- and antisaccade task while undergoing video-based eye-tracking. We analyzed between-group differences in saccade, pupil, blink, and fixation acquisition behaviour. Patients with PD showed previously demonstrated abnormalities (saccade hypometria, antisaccade errors). Relative to controls, LRRK2-NM participants and patients with PD both displayed increased short-latency prosaccades and reduced pupil velocity, plus altered fixation acquisition-less preemptive returning of gaze to the future fixation point location. Interestingly, the effect on blink probability was opposite-higher than controls in LRRK2-NM participants but lower in patients with PD. Future longitudinal studies must confirm the viability of these features as prodromal PD markers.
Competing Interests: Competing interests: D.C.B., B.C.C. and D.P.M. are co-founders of Dynamiris Inc., which is currently developing a clinical tool for neurological and psychiatric disease diagnosis using eye movement data such as that described in this study. All other authors have no other competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: